KR20260085356A - 3,5-2치환 벤젠알키닐 화합물과 면역 체크포인트 저해약을 사용한 암 치료법 - Google Patents

3,5-2치환 벤젠알키닐 화합물과 면역 체크포인트 저해약을 사용한 암 치료법

Info

Publication number
KR20260085356A
KR20260085356A KR1020267016679A KR20267016679A KR20260085356A KR 20260085356 A KR20260085356 A KR 20260085356A KR 1020267016679 A KR1020267016679 A KR 1020267016679A KR 20267016679 A KR20267016679 A KR 20267016679A KR 20260085356 A KR20260085356 A KR 20260085356A
Authority
KR
South Korea
Prior art keywords
compound
salt
present disclosure
once daily
nivolumab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020267016679A
Other languages
English (en)
Korean (ko)
Inventor
가즈히코 요네쿠라
히로시 히라이
가즈아키 마츠오카
Original Assignee
다이호야쿠힌고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다이호야쿠힌고교 가부시키가이샤 filed Critical 다이호야쿠힌고교 가부시키가이샤
Publication of KR20260085356A publication Critical patent/KR20260085356A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020267016679A 2019-02-28 2020-02-28 3,5-2치환 벤젠알키닐 화합물과 면역 체크포인트 저해약을 사용한 암 치료법 Pending KR20260085356A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2019035603 2019-02-28
JPJP-P-2019-035603 2019-02-28
JP2019112619 2019-06-18
JPJP-P-2019-112619 2019-06-18
PCT/JP2020/008527 WO2020175704A1 (ja) 2019-02-28 2020-02-28 3,5-二置換ベンゼンアルキニル化合物と免疫チェックポイント阻害薬とを用いた癌治療法
KR1020217030409A KR20210130774A (ko) 2019-02-28 2020-02-28 3,5-2치환 벤젠알키닐 화합물과 면역 체크포인트 저해약을 사용한 암 치료법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217030409A Division KR20210130774A (ko) 2019-02-28 2020-02-28 3,5-2치환 벤젠알키닐 화합물과 면역 체크포인트 저해약을 사용한 암 치료법

Publications (1)

Publication Number Publication Date
KR20260085356A true KR20260085356A (ko) 2026-06-09

Family

ID=72239799

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020267016679A Pending KR20260085356A (ko) 2019-02-28 2020-02-28 3,5-2치환 벤젠알키닐 화합물과 면역 체크포인트 저해약을 사용한 암 치료법
KR1020267016683A Pending KR20260085357A (ko) 2019-02-28 2020-02-28 3,5-2치환 벤젠알키닐 화합물과 펨브롤리주맙을 사용한 암 치료법
KR1020217030410A Ceased KR20210131387A (ko) 2019-02-28 2020-02-28 3,5-2치환 벤젠알키닐 화합물과 펨브롤리주맙을 사용한 암 치료법
KR1020217030409A Ceased KR20210130774A (ko) 2019-02-28 2020-02-28 3,5-2치환 벤젠알키닐 화합물과 면역 체크포인트 저해약을 사용한 암 치료법

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020267016683A Pending KR20260085357A (ko) 2019-02-28 2020-02-28 3,5-2치환 벤젠알키닐 화합물과 펨브롤리주맙을 사용한 암 치료법
KR1020217030410A Ceased KR20210131387A (ko) 2019-02-28 2020-02-28 3,5-2치환 벤젠알키닐 화합물과 펨브롤리주맙을 사용한 암 치료법
KR1020217030409A Ceased KR20210130774A (ko) 2019-02-28 2020-02-28 3,5-2치환 벤젠알키닐 화합물과 면역 체크포인트 저해약을 사용한 암 치료법

Country Status (8)

Country Link
US (2) US20220184082A1 (cg-RX-API-DMAC7.html)
EP (2) EP3932425A4 (cg-RX-API-DMAC7.html)
JP (7) JPWO2020175704A1 (cg-RX-API-DMAC7.html)
KR (4) KR20260085356A (cg-RX-API-DMAC7.html)
AU (4) AU2020229714B2 (cg-RX-API-DMAC7.html)
MA (2) MA55088A (cg-RX-API-DMAC7.html)
TW (2) TW202045182A (cg-RX-API-DMAC7.html)
WO (2) WO2020175697A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250007056A (ko) 2016-03-04 2025-01-13 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
US11833151B2 (en) 2018-03-19 2023-12-05 Taiho Pharmaceutical Co., Ltd. Pharmaceutical composition including sodium alkyl sulfate
US20220348662A1 (en) * 2019-09-26 2022-11-03 Janssen Pharmaceutica Nv Use of fgfr inhibitors in fgfr-genetically altered cancers to enhance patient response to immune checkpoint inhibitors in sequential treatment settings
WO2025046272A1 (en) 2023-08-31 2025-03-06 Taiho Pharmaceutical Co., Ltd. Methods of treating cancer using futibatinib and pembrolizumab

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004004771A1 (ja) 2002-07-03 2004-01-15 Ono Pharmaceutical Co., Ltd. 免疫賦活組成物
WO2013108809A1 (ja) 2012-01-19 2013-07-25 大鵬薬品工業株式会社 3,5-二置換ベンゼンアルキニル化合物及びその塩
WO2016161239A1 (en) 2015-04-03 2016-10-06 Astex Therapeutics Limited Fgfr/pd-1 combination therapy for the treatment of cancer
WO2017150725A1 (ja) 2016-03-04 2017-09-08 大鵬薬品工業株式会社 悪性腫瘍治療用製剤及び組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040004771A (ko) 2002-07-05 2004-01-16 삼광유리공업주식회사 필름 코팅 유리컵 및 그 제조방법
KR101480809B1 (ko) 2012-03-26 2015-01-09 한국화학연구원 리그닌-폴리에스테르 수지 혼합 분말의 제조 방법 및 이에 따라 제조되는 리그닌-폴리에스테르 수지 혼합 분말
JP6084292B2 (ja) * 2013-07-18 2017-02-22 大鵬薬品工業株式会社 Fgfr阻害剤耐性癌の治療薬
KR20170066546A (ko) * 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
JP6572561B2 (ja) 2015-03-03 2019-09-11 ダイキン工業株式会社 熱交換器および空気調和機
EA201890161A1 (ru) * 2015-06-29 2018-06-29 Верастэм, Инк. Терапевтические композиции, комбинации и способы применения
US10149887B2 (en) * 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
SG10201913538VA (en) * 2015-11-23 2020-02-27 Five Prime Therapeutics Inc Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
JP6409797B2 (ja) 2016-02-24 2018-10-24 三菱電機株式会社 冷蔵庫

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004004771A1 (ja) 2002-07-03 2004-01-15 Ono Pharmaceutical Co., Ltd. 免疫賦活組成物
WO2013108809A1 (ja) 2012-01-19 2013-07-25 大鵬薬品工業株式会社 3,5-二置換ベンゼンアルキニル化合物及びその塩
WO2016161239A1 (en) 2015-04-03 2016-10-06 Astex Therapeutics Limited Fgfr/pd-1 combination therapy for the treatment of cancer
WO2017150725A1 (ja) 2016-03-04 2017-09-08 大鵬薬品工業株式会社 悪性腫瘍治療用製剤及び組成物

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
Cancer Res. 70, 2085-2094(2010)
Cell. 168:707-723(2017)
Cellular Physiology and Biochemistry, 33, p.633-645(2014)
frontirs in Immunology, 9, 2018, Article1310. doi:10. 3389/fimmu. 2018. 01310
J. Clin. Oncol. 24, 3664-3671(2006)
JCO Precision Oncology(DOI:10. 1200/P0.18. 00117) July 24, 2018
Mol. Cancer Res. 3, 655-667(2005)
N. Engl. J. Med., 366:2443-2454(2012)
N. Engl. J. Med., 375:819-829(2016)
Nat. Rev. Cancer 10:116-129(2010)
Nat. Rev. Cancer, 12:252-264(2012)
Oncotarget. 8:16052-16074(2017)
Sci. Transl. Med. 9, eaal3604(2017)
The Breast. 37, 126-133(2018)

Also Published As

Publication number Publication date
MA55091A (fr) 2022-01-05
KR20210131387A (ko) 2021-11-02
EP3932427A1 (en) 2022-01-05
AU2020228514A1 (en) 2021-10-07
AU2025203861A1 (en) 2025-06-19
JP2026116557A (ja) 2026-07-09
JP2024152860A (ja) 2024-10-25
AU2020228514B2 (en) 2025-02-27
JPWO2020175704A1 (cg-RX-API-DMAC7.html) 2020-09-03
MA55088A (fr) 2022-01-05
JP2025075059A (ja) 2025-05-14
US20220184082A1 (en) 2022-06-16
JP2023112136A (ja) 2023-08-10
KR20260085357A (ko) 2026-06-09
AU2025203865A1 (en) 2025-06-19
US20220125793A1 (en) 2022-04-28
KR20210130774A (ko) 2021-11-01
JPWO2020175697A1 (cg-RX-API-DMAC7.html) 2020-09-03
TW202045182A (zh) 2020-12-16
TW202039507A (zh) 2020-11-01
AU2020229714B2 (en) 2025-02-27
WO2020175704A1 (ja) 2020-09-03
EP3932425A1 (en) 2022-01-05
WO2020175697A1 (ja) 2020-09-03
AU2020229714A1 (en) 2021-10-07
JP2023096156A (ja) 2023-07-06
EP3932425A4 (en) 2022-12-07
EP3932427A4 (en) 2022-12-07

Legal Events

Date Code Title Description
A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000